Volume 3.48 | Dec 14

Prostate Cell News 3.48 December 14, 2012
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Enhancer of zeste homolog 2 (EZH2), a subunit of polycomb repressive complex 2, silences gene expression via its histone methyltransferase activity. Researchers found that the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor. [Science] Abstract | Press Release

[Free Webinar] ALDH+ Cancer Precursor Cells in Drug Response Prediction - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)

Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer Through Loss of ABCA1
By performing next-generation sequencing-based DNA methylome analysis, scientists discovered marked hypermethylation at the promoter of the major cellular cholesterol efflux transporter, ABCA1, in LNCaP prostate cancer cells. ABCA1 promoter hypermethylation renders the promoter unresponsive to trans-activation and leads to elevated cholesterol levels in LNCaP. [Cancer Res] Abstract

Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression
Investigators examined primary and metastatic prostate cancer and found that miR-31 expression was reduced as a result of promoter hypermethylation and importantly, the levels of miR-31 expression were inversely correlated with the aggressiveness of the disease. [Cancer Res] Abstract

Role of OGR1 in Myeloid-Derived Cells in Prostate Cancer
Researchers demonstrated that ovarian cancer G-protein-coupled-receptor-1 (OGR1) deficiency in host cells significantly reduced tumorigenesis of prostate cancer in mice. [Oncogene] Abstract

New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells
Using androgen receptor (AR) knockout mice to determine AR functions in selective prostate cancer (PCa) cells, the authors determined that AR might play differential roles in various cell types, either to promote or suppress PCa development/progression. [Am J Pathol] Abstract

Loss of LARGE2 Disrupts Functional Glycosylation of α-Dystroglycan in Prostate Cancer
Scientists showed that the level of expression of the β-dystroglycan (βDG) subunit as well as the glycosylation status of the αDG subunit inversely correlate with the Gleason scores of prostate cancers; furthermore, they showed that the functional glycosylation of αDG is substantially reduced in prostate cancer metastases. [J Biol Chem] Abstract

Akt Mediates Metastasis-Associated Gene 1 (MTA1) Regulating the Expression of E-Cadherin and Promoting the Invasiveness of Prostate Cancer Cells
Scientists demonstrated that the silencing of MTA1 by siRNA treatment results in the upregulation of E-cadherin expression by the phosphorylation of AKT and decreases the invasiveness of prostate cancer cells. [PLoS One] Full Article

δ-Catenin Overexpression Promotes Angiogenic Potential of CWR22Rv-1 Prostate Cancer Cells via HIF-1α and VEGF
The authors revealed that CWR22Rv-1 cells overexpressing δ-catenin display bigger tumor formation and higher angiogenic potentials than their matched control cells in the CAM assay. [FEBS Lett] Abstract

Temperature-Dependent Activation of Differential Apoptotic Pathways during Cryoablation in a Human Prostate Cancer Model
A human prostate cancer model and cells were exposed to temperatures of -60, -30 and -15 °C to simulate a cryoablative procedure. Using a combination of flow-cytometry, fluorescent microscopy and western blot analyses, samples were assessed at various times post thaw to identify the presence, levels and the pathways involved in cell death. [Prostate Cancer Prostatic Dis] Abstract


Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
In this double-blind study, researchers randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free survival and overall survival. [N Engl J Med] Abstract | Press Release

Multicenter Evaluation of [-2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer
The prostate health index, a measure based on [-2]proprostate-specific antigen (p2PSA) and calculated as p2PSA/free PSA √total PSA, was evaluated in a multicenter study for detecting prostate cancer. [Clin Chem] Abstract

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours

Brain Metastases from Prostate Cancer: An Emerging Clinical Problem with Implications for the Future Therapeutic Scenario
Brain metastases from prostate cancer (PC) seem to be more frequent than in the past, possibly because advances in the treatment of patients with castration-resistant PC have prolonged their survival. Furthermore, docetaxel (the drug of choice for the first-line treatment of castration-resistant PC) cannot cross the blood-brain barrier and control metastatic foci. However, this problem may be overcome by new active drugs such as cabazitaxel. [Future Oncol] Abstract

UT MD Anderson, GlaxoSmithKline to Collaborate on New Approach to Cancer Immune Therapy; Success Could Earn Cancer Center $335 Million Plus Royalties
The University of Texas (UT) MD Anderson Cancer Center and GlaxoSmithKline have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer. [The University of Texas MD Anderson Cancer Center] Press Release

Alliance for Regenerative Medicine Forms Tissue Engineering and Biomaterials Committee
The Alliance for Regenerative Medicine announced the formation of a Tissue Engineering and Biomaterials Committee (TEBC). The TEBC has been established to assemble the companies, academic institutions, and organizations within the Alliance for Regenerative Medicine that develop and commercialize tissue engineered and biomaterial based technologies. [Alliance for Regenerative Medicine] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 25th Anniversary Lorne Cancer Meeting
February 14-16, 2013
Lorne, Australia

our events page to see a complete list of events in the prostate cell community.


Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc)

Postdoctoral Position – Biomarkers in Prostate Cancer (Roswell Park Cancer Institute, Buffalo)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Postdoctoral Position – Translational Program in Endocrine-Related Cancers (Baylor College of Medicine)

PhD Student – Multi-Compartment Magnetic Resonance Imaging of Prostate Cancer (University of East Anglia)

Recruit Top Talent : Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us